hi5 Sep 2018 21:27
May have missed some messages but remember people talking about why Sierra made no greater mention of Sar. I asked sierra and here is the answer, hope it may help in some way help holders.
Our licensing agreement for SRA737 is with the CRT Pioneer Fund LP, of which CRT – the commercialization arm of CRUK - is a shareholder; Sareum's involvement substantially predates our engagement with CRT Pioneer Fund, CRT and ICR, and they have subsequently not been engaged in the development program for the asset.
Notwithstanding, we certainly have acknowledged Sareum’s role in the early advancement of SRA737. In our press release announcing the licensing of SRA737 from the CRT Pioneer Fund LP, we note that SRA737 “was discovered and initially developed by scientists in the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research (ICR) in collaboration with Sareum Holdings plc (LSE AIM: SAR), with funding provided by Cancer Research UK, the ICR and Sareum. The program was licensed in September 2013 to the CRT Pioneer Fund, a specialist cancer investment fund established by Sixth Element Capital LLP (6EC), Cancer Research Technology (CRT) and the European Investment Fund (EIF) and managed by 6EC.”